These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 26261845)

  • 1. Generic Pharmaceutical Association (GPhA) - 2015 CMC Workshop (June 9-10, 2015 - Bethesda, Maryland, USA).
    Komlos D
    Drugs Today (Barc); 2015 Jul; 51(7):429-40. PubMed ID: 26261845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abbreviated New Drug Applications: Generic Drug User Fee Amendments Act Analysis of Application Quality Metrics.
    Woo J; Luan JJ; Li Z; Grosser S; Peters J; Chazin H
    Ther Innov Regul Sci; 2019 Sep; 53(5):696-700. PubMed ID: 30360656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA pharmaceutical quality oversight.
    Yu LX; Woodcock J
    Int J Pharm; 2015 Aug; 491(1-2):2-7. PubMed ID: 26027494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA's Generic Drug Program: Decreasing Time to Approval and Number of Review Cycles.
    Chazin H; Woo J; Han J; Grosser S; Luan J
    Ther Innov Regul Sci; 2020 Jul; 54(4):758-763. PubMed ID: 32557293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic Impacts of the Generic Drug User Fee Act Fee Structure.
    Dong K; Boehm G; Zheng Q
    Value Health; 2017 Jun; 20(6):792-798. PubMed ID: 28577697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advancing pharmaceutical quality: An overview of science and research in the U.S. FDA's Office of Pharmaceutical Quality.
    Fisher AC; Lee SL; Harris DP; Buhse L; Kozlowski S; Yu L; Kopcha M; Woodcock J
    Int J Pharm; 2016 Dec; 515(1-2):390-402. PubMed ID: 27773853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common deficiencies with bioequivalence submissions in abbreviated new drug applications assessed by FDA.
    Liu Q; Davit BM; Cherstniakova SA; Dandamudi S; Walters JF; Lee CH; Raines KW; Ren K; Williamson LN; Conner DP
    AAPS J; 2012 Mar; 14(1):19-22. PubMed ID: 22130775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Common Filing Deficiencies in Abbreviated New Drug Applications Containing Clinical Endpoint Studies.
    Fermaglich LJ; Chen R; Kim CY; Chuh EE; Thomas T; Shetty D; Lee J; Young J; Fan Y
    Ther Innov Regul Sci; 2019 Jan; 53(1):81-85. PubMed ID: 29719976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Food and Drug Administration: Helping pharmacists ensure that patients receive high-quality medicines.
    Kremzner M
    J Am Pharm Assoc (2003); 2016; 56(2):201-2. PubMed ID: 27000171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Information Association Pharmacovigilance and Risk Management Strategies 2017: Overview of the Generic Drug Program and Surveillance.
    Chazin HD; Peters JR; Catterson DM; Osterhout JL; Forsyth LM; Lee JE; Kim EK; Feibus KB
    Ther Innov Regul Sci; 2019 Mar; 53(2):249-253. PubMed ID: 29742934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Completeness assessment of type II active pharmaceutical ingredient drug master files under generic drug user fee amendment: review metrics and common incomplete items.
    Zhang H; Li H; Song W; Shen D; Skanchy D; Shen K; Lionberger RA; Rosencrance SM; Yu LX
    AAPS J; 2014 Sep; 16(5):1132-41. PubMed ID: 25034968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interview with Janet Woodcock.
    Woodcock J
    Bioanalysis; 2010 Sep; 2(9):1535-8. PubMed ID: 21083281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generic Pharmaceutical Association (GPhA) - 2015 Annual Meeting (February 9-11, 2015 - Miami Beach, Florida, USA).
    Bowman M
    Drugs Today (Barc); 2015 Feb; 51(2):153-6. PubMed ID: 25756069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical impurities: regulatory perspective for Abbreviated New Drug Applications.
    Basak AK; Raw AS; Al Hakim AH; Furness S; Samaan NI; Gill DS; Patel HB; Powers RF; Yu L
    Adv Drug Deliv Rev; 2007 Jan; 59(1):64-72. PubMed ID: 17196703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Generic Drug User Fee Act (GDUFA) Program for Fiscal Years 2013-2022.
    Friedman EL; Falade LW; Bartlett MG
    AAPS J; 2024 Jul; 26(5):85. PubMed ID: 39043991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leveraging Modeling and Simulation to Enhance the Efficiency of Bioequivalence Approaches for Generic Drugs: Highlights from the 2023 Generic Drug Science and Research Initiatives Public Workshop.
    Pal A; Wu F; Walenga R; Tsakalozou E; Alam K; Gong Y; Zhao L; Fang L
    AAPS J; 2024 Apr; 26(3):45. PubMed ID: 38589695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interview with Janet Woodcock: progress on the FDA's critical path initiative.
    Woodcock J
    Biomark Med; 2009 Dec; 3(6):671-3. PubMed ID: 20477704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs).
    Raw AS; Furness MS; Gill DS; Adams RC; Holcombe FO; Yu LX
    Adv Drug Deliv Rev; 2004 Feb; 56(3):397-414. PubMed ID: 14962589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A network of regulatory innovations to improve FDA quality assessments of human drug applications.
    Tran R; Fraser G; Fisher AC; Lee SL; Boam A; Tsinontides S; Maguire J; Yu LX; Rosencrance S; Kozlowski S; Henry D
    Int J Pharm X; 2024 Jun; 7():100239. PubMed ID: 38545329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Manufacturing Related Deficiencies for Modified Release Tablet in Abbreviated New Drug Applications.
    Chen J; Wang Z; Shah R; Scherlitz A; Feng X; Chen J; Wu L
    AAPS PharmSciTech; 2022 Sep; 23(7):268. PubMed ID: 36168006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.